Elizabeth Pharmacy is seeking a pharmacy technician. If you are interested contact us at 908-994-1525.

FDA

Food and Drug Administration

  • FDA clears first duodenoscope with disposable distal cap

    The U.S. Food and Drug Administration today cleared the first duodenoscope with a disposable distal cap, a new feature that will improve access for cleaning and reprocessing. The Pentax ED34-i10T model duodenoscope is intended to provide visualization and access to the upper gastrointestinal (GI) tract to treat bile duct disorders and other upper GI problems.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576753.htm
    Wed, 20 Sep 2017 11:57:00 -0400
  • Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s continued efforts to promote the safe adoption of medication-assisted treatment for opioid addiction

    Medication-assisted treatment (MAT) – the use of medication combined with counseling and behavioral therapies – is one of the major pillars of the federal response to the opioid epidemic in this country. This type of treatment is an important tool that has the potential to help millions of Americans with an opioid use disorder regain control over their lives. In fact, patients receiving MAT cut their risk of death from all causes in half, according to the Substance Abuse and Mental Health Services Administration. Addressing the epidemic of opioid addiction is my highest public health priority. One element of that effort is promoting more widespread, safe adoption of MAT as a way to help more people overcome addiction.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576752.htm
    Wed, 20 Sep 2017 12:18:00 -0400
  • FDA approves new treatment for adults with relapsed follicular lymphoma

    The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576129.htm
    Thu, 14 Sep 2017 12:56:00 -0400
  • Statement from FDA Commissioner Scott Gottlieb, M.D., about crops impacted by Hurricanes Harvey and Irma and FDA’s work with farmers affected by the storms

    Statement from FDA Commissioner Scott Gottlieb, M.D., about crops impacted by Hurricanes Harvey and Irma and FDA’s work with farmers affected by the storms

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576126.htm
    Thu, 14 Sep 2017 13:48:00 -0400
  • FDA approves first biosimilar for the treatment of cancer

    The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576112.htm
    Thu, 14 Sep 2017 12:11:00 -0400
  • FDA permits marketing of mobile medical application for substance use disorder

    Today, the U.S. Food and Drug Administration permitted marketing of the first mobile medical application to help treat substance use disorders (SUD). The Reset application is intended to be used with outpatient therapy to treat alcohol, cocaine, marijuana and stimulant SUDs. The application is not intended to be used to treat opioid dependence.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576087.htm
    Thu, 14 Sep 2017 11:16:00 -0400
  • Statement from FDA Commissioner Scott Gottlieb, M.D., on a new qualified health claim advising that early introduction of peanuts to certain high-risk infants may reduce risk of peanut allergy

    Statement from FDA Commissioner Scott Gottlieb, M.D., on a new qualified health claim advising that early introduction of peanuts to certain high-risk infants may reduce risk of peanut allergy

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm575008.htm
    Thu, 07 Sep 2017 12:32:00 -0400
  • FDA clears mammography device with option for patient-assisted compression

    Today, the U.S. Food and Drug Administration cleared the first 2D digital mammography system that allows patients to increase or decrease the amount of compression applied to their own breast before the mammogram x-ray is taken.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574562.htm
    Fri, 01 Sep 2017 15:07:00 -0400
  • FDA approves Mylotarg for treatment of acute myeloid leukemia

    The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574507.htm
    Fri, 01 Sep 2017 11:19:00 -0400
  • Statement from Center for Drug Evaluation and Research Director Janet Woodcock regarding safety concerns related to investigational use of Keytruda in multiple myeloma

    Statement from Center for Drug Evaluation and Research Director Janet Woodcock regarding safety concerns related to investigational use of Keytruda in multiple myeloma

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574341.htm
    Thu, 31 Aug 2017 11:08:00 -0400
  • FDA approval brings first gene therapy to the United States

    The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm
    Wed, 30 Aug 2017 10:41:00 -0400
  • FDA approves new antibacterial drug

    The U.S. Food and Drug Administration today approved Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573955.htm
    Tue, 29 Aug 2017 17:56:00 -0400
  • FDA approves first U.S. treatment for Chagas disease

    The U.S. Food and Drug Administration today granted accelerated approval to benznidazole for use in children ages 2 to 12 years old with Chagas disease. It is the first treatment approved in the United States for the treatment of Chagas disease.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573942.htm
    Tue, 29 Aug 2017 16:51:00 -0400
  • Statement from FDA Commissioner Scott Gottlieb, M.D. on the FDA’s new policy steps and enforcement efforts to ensure proper oversight of stem cell therapies and regenerative medicine

    One of the most promising new fields of science and medicine is the area of cell therapies and their use in regenerative medicine. These new technologies, most of which are in early stages of development, hold significant promise for transformative and potentially curative treatments for some of humanity’s most troubling and intractable maladies. Recent advances in our basic knowledge of the pathways involved in tissue damage and regeneration have combined with remarkable progress in adult stem cell biology to put us at a genuine inflection point in the history of medicine. The prospect of clinical tissue repair strategies is a tangible reality. This promise is reinforced by the strong commitment of the investment and scientific communities in exploring the potential applications across a wide range of vexing diseases and conditions, such as cancer, Parkinson’s disease, and diabetes, among many others.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573443.htm
    Mon, 28 Aug 2017 08:56:00 -0400
  • FDA warns US Stem Cell Clinic of significant deviations

    The U.S. Food and Drug Administration today posted a warning letter issued to US Stem Cell Clinic of Sunrise, Florida, and its Chief Scientific Officer Kristin Comella for marketing stem cell products without FDA approval and for significant deviations from current good manufacturing practice requirements, including some that could impact the sterility of their products, putting patients at risk.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573431.htm
    Mon, 28 Aug 2017 08:40:00 -0400
  • FDA acts to remove unproven, potentially harmful treatment used in ‘stem cell’ centers targeting vulnerable patients

    The U.S. Food and Drug Administration took decisive action to prevent the use of a potentially dangerous and unproven treatment belonging to StemImmune Inc. in San Diego, California, and administered to patients at the California Stem Cell Treatment Centers in Rancho Mirage and Beverly Hills, California. On behalf of the FDA, on Friday, Aug. 25, 2017 the U.S. Marshals Service seized five vials of Vaccinia Virus Vaccine (Live) – a vaccine that is reserved only for people at high risk for smallpox, such as some members of the military. Each of the vials originally contained 100 doses of the vaccine, and although one vial was partially used, four of the vials were intact.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573427.htm
    Mon, 28 Aug 2017 08:32:00 -0400
  • Statement from FDA Commissioner Scott Gottlieb, M.D., on the FDA’s role in ensuring Americans have access to clear and consistent calorie and nutrition information; forthcoming guidance will provide greater clarity and certainty

    As a doctor, father and the head of the U.S. Food & Drug Administration, I believe that everyone is entitled to the information they need to make informed decisions about the food they eat. We serve as the nation’s expert on food labeling, which is why Congress entrusted us with the responsibility of crafting predictable, uniform federal standards that will benefit the health of families across America by ensuring access to essential calorie and nutrition information on food and menu labels.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573277.htm
    Fri, 25 Aug 2017 09:29:00 -0400
  • Statement from FDA Commissioner Scott Gottlieb, M.D. – FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    There’s perhaps no more important mandate that we have at the FDA than safeguarding the health and safety of children. For that reason, I believe it’s important that parents and health care providers have the best information available to inform the decisions they make about a child’s health. There are few more common decisions that parents and providers are asked to make than the question of how to appropriately treat a child’s cough and cold symptoms. Sometimes symptoms can be severe enough that prescription medication is needed, but some of these medications pose their own risks – especially for younger children – because they may contain opioids. Other times medication might not be necessary at all.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm572466.htm
    Mon, 21 Aug 2017 09:31:00 -0400
  • FDA provides new tools for the development and proper evaluation of tests for detecting Zika virus infection

    As an additional measure in the fight against Zika virus, today the U.S. Food and Drug Administration announced that it has made available a panel of human plasma samples to aid in the regulatory evaluation of serological tests to detect recent Zika virus infection.

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm572197.htm
    Thu, 17 Aug 2017 15:52:00 -0400
  • FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia

    The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

    https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm572131.htm
    Thu, 17 Aug 2017 13:22:00 -0400

The views and opinions expressed in this feed are those of the authors and do not necessarily reflect the official policy or position of Elizabeth Pharmacy. Elizabeth Pharmacy does not warrant the accuracy, timeliness or completeness of the information contained on this feed. If you have a particular complaint about something you’ve found on this web site, feel free to contact us.